John is a 30-year veteran of the pharmaceutical industry with a track record of creating value for shareholders at public and private companies.
Cangene: $220 million Sale of the Company
President, CEO, Board Member, Cangene Corporation (formerly TSX: CNJ)
2011 – 2014
Transformed Cangene from a biodefense developer/government contractor to a specialty pharmaceutical company
Divested non-core assets
Aligned manufacturing, marketing, and sales force across North America
Acquired Hemophelia assets from Ipsen
Acquired by Emergent BioSolutions in 2014 for $220 million, a 45% premium
Bentley: $375 million Sale of the Company
President, CEO, Bentley Pharmaceuticals (formerly NYSE: BNT) 2005-2008
Expanded nanotechnology programs,
lead the launch of more than 20 new product in the EU
Acquired by Teva Pharmaceutical Industries in 2008 for $375 million
CPEX: $75 million Sale of the Company
Chief Executive Officer, President and Director, CPEX Pharmaceuticals (formerly NASDAQ: CPEX) 2009-2011
Orchestrated the spin-off of CPEX from Bentley as part of the transaction with Teva
Led development/commercialization of patented drug delivery technology
Sold to Footstar in 2011 for $75 million
Sandoz (division of Novartis AG): Increased U.S. Sales to $1.2 Billion
President, Sandoz Inc. 2001–2005
Led efforts to more than double net sales growth and overall profitability
Previously, Mr. Sedor served as President and Chief Executive Officer at Centeon, LLC, a joint venture between two major multinational corporations, Rhône-Poulenc Rorer and Hoechst AG. Previously, Mr. Sedor served as Executive Vice President at Rhône-Poulenc Rorer, Revlon Health Care and Parke-Davis. Mr. Sedor holds a Bachelor of Science degree in Pharmacy/Chemistry from Duquesne University, and has studied strategic marketing at both Northwestern University’s Kellogg Graduate School of Management and Harvard Business School. He has also attended Harvard’s Executive Forum.
Currently, Mr. Sedor is a Board Member, Pernix Therapeutics (NASDAQ: PTX), a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. He also serves on the Board of Directors for Velico Medical Inc, a clinical-stage company developing product-candidates for blood transfusions safety.
Morgan Stanley Boosts Position in Pernix Therapeutics Holdings Inc (PTX)
Posted by Shane Hupp on May 4th, 2016 // No Comments
Pernix Therapeutics Holdings logoMorgan Stanley raised its stake in shares of Pernix Therapeutics Holdings Inc (NYSE:PTX) by 48,456.0% during the fourth quarter, Holdings Channel reports. The fund owned 5,160,043 shares of the specialty pharmaceutical company’s stock after buying an additional 5,149,416 shares during the period. Morgan Stanley owned about 8.45% of Pernix Therapeutics Holdings worth $15,222,000 at the end of the most recent quarter.
Pernix Therapeutics Holdings Inc (NYSE:PTX) traded down 3.64% during trading on Wednesday, reaching $1.06. 7,532,120 shares of the company’s stock were exchanged. Pernix Therapeutics Holdings Inc has a 12 month low of $0.73 and a 12 month high of $7.10. The firm has a 50 day moving average of $0.98 and a 200-day moving average of $2.17. The stock’s market cap is $64.72 million.
Pernix Therapeutics Holdings (NYSE:PTX) last posted its quarterly earnings results on Thursday, March 10th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter, missing the consensus estimate of $0.01 by $0.60. On average, equities research analysts anticipate that Pernix Therapeutics Holdings Inc will post $0.09 earnings per share for the current fiscal year.
Several research firms recently issued reports on PTX. Zacks Investment Research raised shares of Pernix Therapeutics Holdings from a “sell” rating to a “hold” rating in a research report on Friday, April 29th. Brean Capital reissued a “buy” rating and issued a $5.00 price target on shares of Pernix Therapeutics Holdings in a research report on Thursday, March 31st. S&P Equity Research reduced their price target on shares of Pernix Therapeutics Holdings from $1.37 to $1.12 in a research report on Wednesday, March 23rd. Oppenheimer downgraded shares of Pernix Therapeutics Holdings from an “outperform” rating to a “market perform” rating